The future of pharmaceuticals.
Laxxon Medical is disrupting the current pharmaceutical drug delivery and manufacturing landscape through our innovative, patented SPID®-Technology (Screen Printing Innovational Drug Technology).
About Us
Laxxon Medical holds the exclusive worldwide rights to the commercial use and application of SPID® Technology, a patented large-scale 3D screen printing process.
With SPID® Technology, it is possible for the first time to develop unique oral, transdermal and implantable dosage forms with complex Drug Delivery Systems (DDS).
SPID® Technology shapes and distributes active ingredients within each printed unit to develop optimized dosage forms that can be produced on an industry scale.
The Laxxon Medical management team has over 20 years of experience in the pharmaceutical industry.
We are headquartered in New York City with a lab in Jena, Germany, as well as a NYC lab arriving in 2022.
$190B Problem
In the next 10 years,
150+ drugs will come off patent protection. These drugs are worth $190 Billion in sales.
Our Solutions
Technology transfer patent "extension"
Innovative Drug Delivery
with Premium R&D
Production of New Drugs
505b2 Registration
Our Technology
Advanced 3D Printing for Pharmaceutical Solutions
Our goal is to establish SPID®-Technology as a manufacturing process that has the individual and the pharmaceutical partner in mind. SPID®-Technology revolutionizes the pharmaceutical experience for the individual because of its ability to target the release of active ingredients in the tablet. For contractual partners, SPID®-Technology provides extended protection through technology transfer for existing and future products with the extensive IP of Laxxon Medical.